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Multifocal Electroretinogram Findings after Intravitreal 
Bevacizumab Injection in Choroidal Neovascularization of 
Age-Related Macular Degeneration
Joo Youn Park, Seung Hoon Kim, Tae Kwann Park, Young-Hoon Ohn
Department of Ophthalmology, Soonchunhyang University College of Medicine, Bucheon, Korea
Purpose: To evaluate the changes in multifocal electroretinogram (mfERG) and optical coherence tomography 
(OCT) after intravitreal bevacizumab injection in the treatment of age-related macular degeneration (AMD). 
Methods: Twenty-one eyes with choroidal neovascularization secondary to AMD were studied before and after 
intravitreal bevacizumab injection for best corrected visual acuity (BCVA), OCT, and mfERG. 
Results: The BCVA improved, while central macular thickness and total macular volume in OCT decreased af-
ter intravitreal bevacizumab injection (p = 0.03, 0.01, and 0.01, respectively). In mfERG, the amplitude of P1, and 
implicit time of P1 and N1 indicated a statistically significant improvement of retinal response after intravitreal 
bevacizumab injection.
Conclusions: There is a potential role for mfERG in evaluating the effect on retinal function of intravitreal bev-
acizumab injection.
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Age-related macular degeneration (AMD) is the leading 
cause of legal blindness in people over the age of 65 years, 
and severe decreased visual acuity is believed to be due to 
choroidal neovascularization (CNV) [1,2]. 
Vascular endothelial growth factor (VEGF) has been im-
plicated as a major stimulus for CNV in AMD, and in the 
breakdown of the blood retina barrier, with increased vascular 
permeability resulting in retinal edema [3,4].
 As a consequence, 
VEGF inhibitors have been launched recently for the treat-
ment of CNV in the clinical field [5-7]. Among them, bev-
acizumab (Avastin
®; Genentech, San Francisco, CA, USA), a 
recombinant humanized monoclonal antibody to human VEGF, 
was approved by the U.S. Food and Drug Administration for 
the treatment of metastatic colorectal cancer on February, 
2004. Previous studies have revealed that intravitreal bev-
acizumab injection improved vision, but these studies con-
cluded from subjective changes of visual acuity and anatomi-
cal changes after injection [8-11]. Recently, several studies 
have assessed the electrophysiological effect of intravitreal 
bevacizumab [12-14]. The aim of this study is to evaluate the 
electroretinographic changes of the macula in eyes with CNV 
due to AMD by means of multifocal electroretinography 
(mfERG), which reflects retinal function objectively [15], 
and optical coherence tomography (OCT), before and after 
intravitreal bevacizumab injection. 
Materials and Methods
The present study was designed as a retrospective study of 
eyes with CNV secondary to AMD treated with intravitreal 
bevacizumab injection between March, 2008 and April, 
2009. Medical records of patients who underwent intravitreal 
injections of bevacizumab for CNV due to AMD were reviewed. 
Patients who had ocular diseases such as high myopia or dif-
fuse retinal degeneration that might influence the mfERG 
were excluded from the study. 
Each patient received three intravitreal injections of bev-
acizumab (1.875 mg / 0.075 mL) at six week intervals (one at 
baseline, and then at six and 12 weeks later) under sterile Korean J Ophthalmol Vol.25, No.3, 2011
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Fig. 1. Stimulus array of 103 hexagonal elements; ring 1, ring 2, 
and ring 3 correspond to the fovea, parafovea, and perifovea, 
respectively. ILM = internal limiting membrane; RPE = retinal pig-
ment epithelium.
A  Changes in best corrected visual acuity
B  Changes of central macular thickness
C  Changes of total macular volume
Fig. 2. Changes in best corrected visual acuity (A), central macular 
thickness (B), and total macular volume (C) before and after intra-
vitreal injection (Wilcoxon's signed rank test, p < 0.05). logMAR 
= logarithm of the minimum angle of resolution.
conditions in an operating room. Postoperative antibiotics 
(ofloxacin; Tarivid, Santen, Japan) were applied four times per 
day for seven days. 
Each patient underwent a baseline screening, including 
slit-lamp examination and best corrected visual acuity (BCVA; 
logarithm of the minimum angle of resolution [logMAR]) 
testing, Cirrus OCT (Carl Zeiss Meditec, Dublin, CA, USA), 
and mfERG. One month after completion of the three in-
jections, the patients were examined. All tests were per-
formed on the same day. Cirrus OCT was performed with the 
512 × 128 scan pattern. Research software (Research Browser 
ver. V.2.0.0.62, Carl Zeiss Meditec) was used to extract central 
macular thickness (CMT), including a circular 1-mm radius 
area around the fovea; total macular volume (TMV) was cal-
culated from an area of 6 × 6 mm with the midpoint centered 
on the fovea. These calculations were based on the retinal 
segmentation algorithm of the Cirrus OCT prototype device.
MfERG recordings were performed using VERIS ver. 4.2 
(EDI, San Mateo, CA, USA). The patients’ pupils were di-
lated using a mixture of 0.5% tropicamide and 0.5% phenyl-
ephrine hydrochloride (Mydrin-P; Santen Pharmaceuticals, 
Osaka, Japan), and the eye to be tested was anesthetized us-
ing proparacaine hydrochloride 0.5% (Alcaine; Alcon, Fort 
Worth, TX, USA). A Burian-Allen bipolar electrode was in-
serted under 99% contrast and high luminance of 200 cd/m
2. 
The stimulus matrix consisted of 103 hexagonal elements 
displayed on a CRT color monitor driven at 75 Hz. The filter 
setting band pass was 5 to 100 Hz and the duration of the data 
acquisition was 4 minutes divided into eight sessions of 30 
seconds. The amplitude of each local response was estimated 
as the dot product between the normalized response template 
and each local response (scalar product method). The 
mfERG stimulus locations and anatomic areas corresponded 
roughly as follows: ring 1 to the fovea, ring 2 to the parafo-
vea, and ring 3 to the perifovea (Fig. 1). The amplitude of 
each group was scaled to reflect the angular size of the stim-
ulus hexagon, which produces the response. These averages 
give a more accurate view of the relative response densities 
of each group. The recordings used the first-order kernel 
component of the mfERG, which is the largest mfERG re-
sponse derived with a biphasic waveform characterized by an 
initial negative deflection (N1), followed by a positive peak 
(P1). This study included the amplitude and implicit time of 
N1 and P1 in rings 1, 2, and 3. To reduce errors by testers, on-
ly one tester performed all tests and determined the peak 
points of responses. 
For the statistical analysis, the results from participants 
were analyzed by Wilcoxon's signed rank test in SPSS ver. 
14.0 (SPSS Inc., Chicago, IL, USA). In addition, Spearman 
rank test and linear correlation analysis were used in order to 
evaluate the correlation with changes of mfERG components, 
the best visual acuity, and changes of OCT components. 
Differences and correlations were considered to be significant JY Park, et al. MfERG after Intravitreal Bevacizumab Injection
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A  Changes of N1 amplitude after injection
B  Changes of P1 amplitude after injection
Fig. 3. Changes of N1 (A) and P1 (B) amplitude in multifocal elec-
troretinogram before and after intravitreal injection (Wilcoxon's 
signed rank test, p < 0.05). 
A  Changes of N1 implicit time after injection
B  Changes of P1 implicit time after injection
Fig. 4. Changes of N1 (A) and P1 (B) implicit time in multifocal 
electroretinogram before and after intravitreal injection (Wilcoxon's
signed rank test, p < 0.05).
Table 1. Correlation with parameters of multifocal electroretinography and best corrected visual acuity (BCVA)
P1 amplitude Ring 1 implicit time Ring 2 implicit time Ring 3 implicit time
Ring 1 Ring 2 Ring 3 N1 P1 N1 P1 N1 P1
BCVA (correlation coefficient)
* 0.08 - 0.12 0.26 0.7 0.35 - 0.03 0.03 - 0.12 - 0.20
BCVA (p-value) 0.81  0.71 0.43 0.01 0.26  0.94 0.94 - 0.71 - 0.54
*Spearman’s Rho, p <0 . 0 5 . 
Table 2. Correlation between parameters of multifocal electroretinography responses and central macular thickness 
(CMT)
P1 amplitude Ring 1 implicit time Ring 2 implicit time Ring 3 implicit time
Ring 1  Ring 2  Ring 3  N1 P1 N1 P1 N1 P1
CMT (correlation coefficient)
* 0.03 0.32 0.19 - 0.04 - 0.3 - 0.16 - 0.34 0.39 0.28
CMT (p-value) 0.93 0.32 0.56  0.91  0.93  0.63  0.29 0.21 0.37
*Spearman’s Rho, p <0 . 0 5 . 
when p < 0.05.
Results
Twenty eyes (14 patients) with CNV secondary to AMD 
were included. The mean patient age was 55.9 ± 13.9 years. 
Before injection, the mean best corrected visual acuity 
(BCVA) was 0.66 ± 0.29 (logMAR ± SD). The mean BCVA 
improved to 0.52 ± 0.32 (logMAR ± SD) after treatment (p = 
0.03) (Fig. 2A). The mean CMT measured by OCT at base-
line was 319.43 ± 128.09 μm. At one month post injection, 
the mean CMT measurement had decreased to 268.29 ± 72.09 
μm (Fig. 2B). Statistically significant difference was found 
between the CMT at baseline and after treatment (p = 0.04). 
TMV was 11.65 ± 2.45 mm
3 before treatment and decreased 
to 10.52 ± 1.78 mm
3 after treatment. There was significant 
improvement in TMV after injection (p = 0.01) (Fig. 2C).
In mfERG, the amplitude of N1 in rings 1 to 3 changed after Korean J Ophthalmol Vol.25, No.3, 2011
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Table 3. Correlation between parameters of multifocal electroretinography and total macular volume (TMV)
P1 amplitude Ring 1 implicit time Ring 2 implicit time Ring 3 implicit time
Ring 1  Ring 2  Ring 3  N1 P1 N1 P1 N1 P1
TMV (correlation coefficient)
* - 0.36 - 0.03 0.38 0.46 0.26 - 0.04 0.36 0.05 - 0.01
TMV (p-value) 0.26 0.93 0.23 0.13 0.42 0.91 0.25 0.88 0.97
*Spearman’s Rho, p <0 . 0 5 . 
treatment, but no statistically significant differences were 
found (ring 1, p = 0.18; ring 2, p = 0.27; ring 3, p = 0.55) (Fig. 3A). 
The amplitude of P1 in rings 1 to 3 increased after injection 
with statistical significance (ring 1, p = 0.03; ring 2, p = 0.04; 
ring 3, p = 0.02) (Fig. 3B). From ring 1 to 3, the implicit time 
of N1 and P1 decreased after injection compared with base-
line, and statistical analysis revealed significant difference 
(P1: ring 1, p = 0.02; ring 2, p = 0.01; ring 3, p = 0.03; N1: ring 1, 
p = 0.01; ring 2, p = 0.02; ring 3, p = 0.01) (Fig. 4).
There appeared to be a linear relationship between changes 
of N1 implicit time in ring 1 and the BCVA however, other 
factors had no significant difference (Table 1). The correla-
tion between CMT and mfERG values was not significant 
(Table 2). The TMV correlated with the implicit time of N1 
and P1 in ring 1, P1 in ring 2, and N1 in ring 3, but without 
statistical significance. A reverse correlation was seen be-
tween TMV and amplitude in rings 1 and 2, but not at a sig-
nificant level (Table 3).
Discussion
Bevacizumab is a recombinant humanized monoclonal an-
tibody to human VEGF that binds to VEGF and blocks it 
from binding to its receptors in tumor tissues. Intravitreal 
bevacizumab injection is increasingly used as an off-label 
therapy in ophthalmology, and shows benefits in the im-
provement of visual acuity and anatomical changes of many 
eye diseases [8-14,16].
As we hypothesized, visual acuity and anatomical changes 
were associated with functional changes of the retina, thus 
we used mfERG, which assesses retinal function, to confirm 
functional changes after injection. The use of mfERG en-
ables topographic mapping of retinal function in the central 
30° of the retina. Recent studies revealed that the human 
mfERG response is dominated by cells of the outer retina, 
such as the photoreceptors and the ON- and OFF-bipolar 
cells, than cells from the inner retina [17,18].
 Accordingly, 
mfERG response is useful in evaluating cone cells in pro-
portion to bipolar cells, while the amplitude and implicit time 
show retinal functions principally [19].
 Any damage to the 
receptor that destroys the cell or reduces its responsiveness 
will lead to a decrease in the mfERG response amplitude. 
The result showed that intravitreal bevacizumab injection 
has clinical benefit in CNV secondary to AMD in terms of 
visual acuity, CMT, TMV, and mfERG response. These find-
ings are similar to those of previous studies [8-14,16]. Before 
injection, the amplitude of P1 and N1 decreased to less than 
normal values, representing impaired retinal function. The 
amplitude of P1 increased in rings 1, 2, and 3 after injection, 
and the changes of amplitude were significantly different. On 
the other hand, the amplitude of N1 showed no significant 
change after injection. The changes of the P1 amplitude were 
more significant than those of N1. The P1 amplitude is be-
lieved to be linked to the number and function of photo-
receptor cells [19-22]. Damage of the photoreceptor outer 
segment will reduce the P1 amplitude and result in delays of 
its implicit time [18]. In this study we assumed that bipolar 
and other outer retina cells have more of an effect on P1 
waveforms than N1 waveforms [22,23]. Unlike previous 
studies [12-14], we evaluated not only the change of the am-
plitude, but the change of the implicit time after intravitreal 
bevacizumab injection. The implicit times of P1 and N1 were 
prolonged before and after injection compared with normal 
values. The delayed P1 implicit time was due to delay in bi-
polar cell response of the outer retina [19]. It is also possible 
that the delay in the N1 implicit time reflected damage to the 
inner retinal layers, as well as the outer retina [22].
 In our 
study the implicit times of P1 and N1 in rings 1, 2, and 3 
showed statistically significant improvement compared with 
amplitude. Implicit time has been shown to be more sensitive 
than amplitude in CNV as well as other conditions, such as 
diabetes [24], retinitis pigmentosa [25,26], and macular dys-
trophy [27]. The implicit time is thought to be more susceptible 
than the amplitude to injury of photoreceptors and the outer 
plexiform layer [19,22,23,28].
 Although mfERG responses 
after injection improved compared with the baseline, the am-
plitude and implicit time were in the sub-normal range. 
Analysis showed that intravitreal bevacizumab injection 
contributed to improvement of retinal function, but did not 
result in complete recovery.
In a study on 18 eyes with AMD by Moschos et al. [13], 
there was improvement of visual acuity, mfERG response, 
and OCT parameters after intravitreal bevacizumab in-
jection, but there was no correlation between values. Maturi 
et al. [14] studied nine patients with AMD after injection and 
found patients to have significantly higher amplitude com-
pared with baseline, but no correlation was found between 
amplitude and visual acuity or CMT. Also, these findings 
show that BCVA, CMT, TMV, the amplitude, and implicit 
time of mfERG had no obvious correlation, except for the 
implicit time of N1 in ring 1 and the BCVA. 
From the results, we observed less correlation between 
mfERG responses and improvement of visual acuity and ana-
tomical changes, as mfERG waveforms reflect not only the JY Park, et al. MfERG after Intravitreal Bevacizumab Injection
165
photoreceptor layer, but also bipolar and other cells in the in-
ner retina. Also, the amplitude and implicit time can be influ-
enced by injury or atrophy of the retina, particularly of the 
photoreceptor layer and retinal pigment epithelium. Such in-
juries may alter retinal function, which cannot be measured 
by changes of visual acuity and anatomy. Therefore, measuring 
only visual acuity or anatomical changes might miss information 
regarding retinal function that might be observed if the ob-
jective parameter was included. Evaluation with retinal func-
tion can offer more comprehensive information in order to 
make detailed assessments of effective treatment. 
In conclusion, intravitreal bevacizumab injection improved 
patients’ visual acuity and caused anatomical changes in 
CNV secondary to AMD. Furthermore, intravitreal injection 
of bevacizumab resulted in improvement of mfERG responses, 
especially the implicit time compared with amplitude. There 
is a potential role for mfERG in assessing the functional 
changes of the central retina after intravitreal bevacizumab 
injection.  
To better evaluate objective changes of retinal functions 
using mfERG after intravitreal bevacizumab injection, fur-
ther prospective randomized controlled clinical trials will be 
needed, with scheduled re-injections and longer follow-up 
intervals. 
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